Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties
Source abstract
Abstract
Accurate and efficient delivery of genome editing plasmids to targeted cells is of critical importance in genome editing. Herein, we prepared a multifunctional delivery vector with a combination of ligand-mediated selectivity and peptide-mediated transmembrane function to effectively deliver plasmids to targeted cancerous cells. In the delivery system, the clustered regularly interspaced short palindromic repeat-associated Cas9 nuclease (CRISPR-Cas9) plasmid is combined with protamine with membrane and nuclear translocating activities and co-precipitated with CaCO3, which is further decorated by AS1411-functionalized carboxymethyl chitosan and cell penetrating peptide (TAT)-functionalized carboxymethyl chitosan. The AS1411-mediated tumor cell/nuclear targeting and TAT-induced enhanced endocytosis result in obviously increased cellular uptake and nuclear transport. As a result, the CRISPR-Cas9 plasmid can be efficiently delivered to cancer cell nuclei to mediate genome editing, resulting in an efficacious knockout of CTNNB1 gene encoding β-catenin. More importantly, downregulation of β-catenin could effectively prevent its enrichment in nuclei and then significantly downregulate the expression of proteins, such as vimentin, Snail, MMP-2, MMP-9, CD44, Nanog, and Oct4 to prevent tumor progression and metastasis. The edited cancerous cells exhibit favorable remodulated properties including inhibited growth, suppressed migration and invasion, and reduced cancer stemness.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · RNA Interference and Gene Delivery · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan 430072, People’s Republic of China
Department of Pharmacy, The Renmin Hospital of Wuhan University, Wuhan 430060, People’s Republic of China
Funding
National Natural Science Foundation of China
References (46)
Show source-provided references
1. 10.1038/nature0794310.1038/nature07943 ↗
2. 10.1038/nature1581810.1038/nature15818 ↗
3. 10.1146/annurev-biophys-062215-01082210.1146/annurev-biophys-062215-010822 ↗
4. 10.1038/nrc395010.1038/nrc3950 ↗
5. 10.1038/nature2426810.1038/nature24268 ↗
6. 10.1016/j.biomaterials.2018.04.03110.1016/j.biomaterials.2018.04.031 ↗
7. 10.1021/acs.chemrev.6b0079910.1021/acs.chemrev.6b00799 ↗
8. 10.1038/ncomms1077010.1038/ncomms10770 ↗
9. 10.1126/sciadv.150045410.1126/sciadv.1500454 ↗
10. 10.1101/gad.264861.11510.1101/gad.264861.115 ↗
11. 10.1089/hum.2015.08710.1089/hum.2015.087 ↗
12. 10.1002/adfm.20170303610.1002/adfm.201703036 ↗
13. 10.1002/anie.20150603010.1002/anie.201506030 ↗
14. 10.1021/acs.biomac.8b0051110.1021/acs.biomac.8b00511 ↗
15. 10.1021/acsnano.7b0787410.1021/acsnano.7b07874 ↗
16. 10.1002/anie.20161020910.1002/anie.201610209 ↗
17. 10.1016/j.jconrel.2017.09.01310.1016/j.jconrel.2017.09.013 ↗
18. 10.1021/acsnano.6b0760010.1021/acsnano.6b07600 ↗
19. 10.1002/advs.20170017510.1002/advs.201700175 ↗
20. 10.1021/jacs.7b1175410.1021/jacs.7b11754 ↗
21. 10.1021/acs.molpharmaceut.7b0109310.1021/acs.molpharmaceut.7b01093 ↗
22. 10.1021/acsami.7b1332810.1021/acsami.7b13328 ↗
23. 10.1016/j.yexmp.2009.01.00410.1016/j.yexmp.2009.01.004 ↗
24. 10.1016/j.actbio.2018.03.03010.1016/j.actbio.2018.03.030 ↗
25. 10.1016/j.jconrel.2012.09.01910.1016/j.jconrel.2012.09.019 ↗
26. 10.1021/acs.biomac.8b0029210.1021/acs.biomac.8b00292 ↗
27. 10.1016/j.bmcl.2017.12.03510.1016/j.bmcl.2017.12.035 ↗
28. 10.1016/j.ejps.2015.04.00910.1016/j.ejps.2015.04.009 ↗
29. 10.1016/j.mtchem.2017.01.00610.1016/j.mtchem.2017.01.006 ↗
30. 10.1039/C8NR05294H10.1039/C8NR05294H ↗
31. 10.1016/j.cell.2006.10.01810.1016/j.cell.2006.10.018 ↗
32. 10.2147/OTT.S11793310.2147/OTT.S117933 ↗
33. 10.1038/nature2516710.1038/nature25167 ↗
34. 10.1016/j.bmc.2013.02.05010.1016/j.bmc.2013.02.050 ↗
35. 10.1038/nm.421910.1038/nm.4219 ↗
36. 10.1038/nature1440410.1038/nature14404 ↗
37. 10.1016/j.carbpol.2016.04.04110.1016/j.carbpol.2016.04.041 ↗
38. 10.7150/jca.1972310.7150/jca.19723 ↗
39. 10.1038/mt.2013.23310.1038/mt.2013.233 ↗
40. 10.1186/1471-2164-15-7410.1186/1471-2164-15-74 ↗
41. 10.18632/oncotarget.1521010.18632/oncotarget.15210 ↗
42. 10.1007/s10529-017-2491-210.1007/s10529-017-2491-2 ↗
43. 10.1038/nchembio.251010.1038/nchembio.2510 ↗
44. 10.1016/j.ejphar.2013.12.00410.1016/j.ejphar.2013.12.004 ↗
45. 10.1002/jcp.2570610.1002/jcp.25706 ↗
46. 10.1016/j.ijpharm.2017.06.02210.1016/j.ijpharm.2017.06.022 ↗